Good News for our untreated Canadian members!
This latest approval is based on the Phase 3 ECOG1912 study (also referred to as E1912) that demonstrated newly diagnosed patients age 70 or younger (median age of 58) treated with IMBRUVICA® plus rituximab had significantly improved progression-free survival (PFS) compared to patients treated with fludarabine, cyclophosphamide and rituximab (FCR). The risk of disease progression or death was reduced by 66 per cent in the IMBRUVICA® arm compared with FCR, with a median follow-up time of 37 months.
newswire.ca/news-releases/h...
Now it's just a matter of waiting for provincial funding...
Neil